RxDoctor Payments Data

Georgia Patsiopoulos

Optometrist · Warwick, RINPI 1245331982

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (44.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Johnson & Johnson Vision Care, Inc. accounts for 67.1% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2024 at $3,397 and has fallen 82.3% since, to $602 in 2025. Among optometrist clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,925in general payments, 2019–2025

Across 170 payments — averaging $52.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Vision Care, Inc.$6K
  • Sun Pharmaceutical Industries Inc.$589
  • Alcon$378
  • AbbVie$354
  • Oyster Point Pharma, Inc.$278
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$278
  • plus $1K from 9 others

What the payments were for

  • Consulting fees$3,00034%
  • Travel & lodging$1,97322%
  • Food & beverage$3,95244%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,925 in reported general payments places this provider in the 95th percentile of 226 optometrist providers in Rhode Island.

See all optometrist providers in Rhode Island

Medicare billing

Part B allowed, 2024
$28,321
Medicare patients
158
Services billed
545

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine24$14,565
Prednisolone Acetate15$515
Latanoprost60$480
Timolol Maleate50$457
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha35$385

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$354$14,56524 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 226 optometrist providers in Rhode Island.

Other optometrist in Warwick

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →